Increasing the sample size of the cohort to include statistically significant data in VCP genotype–phenotype comparisons can help to analyze the progression in participants with other comorbidities such as ALS, PDB, and peripheral neuropathy. The gene discussed is VCP; the disease is amyotrophic lateral sclerosis.